



Drug Utilization Review Board Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
July 20, 2022	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 and WebEx

[* Click HERE for Meeting Documents *](#)

Board Members Present:

Susan Abdel-Rahman, PharmD
Kimberly Eisenstein, MD
Lisa Pierce, MD
Ginger Nicol, MD, CEDS
Rick Kegler, PharmD
Charlene Hyde, PharmD
Julie Ferguson, DO

Board Members Absent:

Jennifer Passanise, FNP-BC
Stacy Mangum, PharmD
Sandra Bollinger, PharmD

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations Manager
Olivia Rush, PharmD, Program Integrity Pharmacist
Elizabeth Sissom, RN, Clinical Management
Nikki Ashley, Pharmacy Program Specialist
Carmen Burton, Administrative Assistant
Timothy Kling, MD, Acting Medical Director
Elizabeth Short, Program Development Specialist
Connie Sutter, Fiscal Manager
Ambra Stotler, CPhT, Benefit Program Senior Specialist
Lisa Smith, RFP Coordinator
Vicki Benz, Medicaid Drug Rebate Senior Specialist
Pat Borgmeyer, Medicaid Drug Rebate Senior Specialist

Contractors in Attendance:

April Ash, PharmD, Conduent
Blake Shrout, PharmD, AAHIVP, Conduent
Jennifer Colozza, PharmD, Conduent
Megan Fast, PharmD, Conduent
Paul Fung, PharmD, MHA Conduent
Chelsea Pendleton, RN, BSN, Wipro
Geri Roling, RN, Wipro
Ashley Lytton, RN, BSN, Wipro
Sandy Kapur, PharmD, Gainwell Technologies
Karen Powell, PharmD, MS, Gainwell Technologies
Amanda Williams, PharmD, RPh, Gainwell Technologies
Mary-Beth Plum, PharmD, Conduent
Serena Barden, PharmD, BCPS, Gainwell Technologies

Others Attending:

Brian Strickland
Brooke Wilkins
Dana Pipkin
Dave Poskey
David Large
Doug Wood
Eric
Erin Hohman
Heather Higgins

James Baumann
Jeff K
Jennifer Davis
John Bullard
Jordan Kho
JT Mathis
Julie Cair
Kathrin Kucharski
Kim Witte

Kurt Hendrickson
Lisa Tracz
Mark Kaiser
Megan Bell
Melissa Basil
Michael Hooks
Michele Shirley
Nila Stevens
Robert Firnberg

Robin Selsor
Sean Jones
Sara Hovland
Theresa Martinez
Tim
Wardl7

DRAFT

Welcome, Introductions and Opening Remarks	<p>Susan Abdel-Rahman, Board Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself and facilitated the meeting on behalf of the MO HealthNet Division.</p>
Minutes Review	<p>Discussion: Minutes were reviewed from the April 2022 meeting.</p> <p>Decision: The Board voted to accept these approved minutes with no revisions.</p>
Pharmacy Program and Budget Update	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - July 2021-May 2022 Eligibles by Group - July 2021-May 2022 Expenditures by Enrollment Group - July 2021-May 2022 Expenditures by Service - FY22 Pharmacy Spend vs July-May 2022 Total Medicaid Spend - Oct 2021-May 2022 Medicaid Expansion Participants, Expenditures, and Claim Count - July 2021 – June 2022 Pharmacy Expenditures - Pharmacy Program Top 4 Drug Classes per FY - Hep C FY 2018 – FYTD 2022 - Mavyret Expenditures July 2019 – June 2022 - FY2019 – FYTD2023 Rare Disease Expenditures Per Day - Pharmacy Dashboard Drug Reimbursement Trends 2021-2022 - Pharmacy Dashboard Drug Reimbursement Per User Per Month Trends 2021-2022
Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm</p>

New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o JT Mathis with Xeris on Recorlev <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

Clinical and Fiscal Edit Review	
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Ampyra o Botulinum Toxin o Duchenne Muscular Dystrophy (DMD) o Emsam o Gamifant o Immunoglobulin o Koselugo o Luxturna o Narcolepsy Inhibitors o Neuromyelitis Optica Spectrum Disorder (NMOSD) o Nuedexta o Oxandrin o Palforzia o Palynziq o Ranexa o Reblozyl o Selective Serotonin Reuptake Inhibitors (SSRI) o Synagis o Tepezza o Tolvaptan o Transthyretin-Mediated Amyloidosis (ATTR) o Xcopri o Zometa - Public comment provided by: <ul style="list-style-type: none"> o Sara Hovland with Bristol Myers Squibb on Reblozyl; the speaker informed the group that there were updated NCCN guidelines published recently; MHD to take the information back and update proposal as necessary <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

Besremi Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Michael Hooks with Pharmaessentia <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
CAR-T Cell Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Sara Hovland with Bristol Myers Squibb on Breyanzi; the speaker informed the group Breyanzi received two new indications in late June and the current proposal did not reflect those updates; Josh explained that these proposals were prepared prior to June DPAC therefore those changes are not reflected today, however, MHD is aware of the updated label and are making changes as needed <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Crysvita Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Enjaymo Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Enzyme Deficiency, Select Agents Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose from the Board Chair on the ability for MHD to transparently approve criteria based on lab values; MHD currently does not have the functionality as the data received is not great and correctly identifying lab values in the data has proven difficult in the past. - Public comment provided by: <ul style="list-style-type: none"> o Jordan Kho with Agios Pharmaceuticals on Pyrukynd <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Iron, Injectable Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Manufacturers Requiring Prior Authorization Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose from the Board Chair on the anticipated frequency of the updates to the edit; Josh explained there may be updated every quarter. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Psychotropic Medications Polypharmacy Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - The Board Chair agreed that the Board would be interested in seeing a breakdown of the number psychotropics participants are utilizing. - Questions arose from Dr. Pierce on the count of psychotropics a participant must be on before a rejection is seen at point of sale; Josh provided clarification on those numbers for each group in the edit, including those taking seizure medications, those aged < 6 and those aged ≥ 6. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Parathyroid Hormone (PTH) and Bone Resorption Suppression Related Agents Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with the change above in blue.</p>
<p>Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Vyvgart Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

Other Business	
Program Utilization Information – Conduent Update	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 3rd Quarter 2022 (January, February, March) - Top 25 Drugs by Paid Number 3rd Quarter 2022 (January, February, March) - Call Center User Statistics May 2022 <ul style="list-style-type: none"> o The Board Chair asked how the calls for opioids and MME were trending; it was explained that this report is reflective of May 2020 data and many changes were made just in April therefore those trends would not be present in this report - CyberAccess Logging Information - New Drug Statistics May 2022
RetroDUR Update	<p>Paul Fung with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Recent RetroDUR Interventions: <ul style="list-style-type: none"> o Concurrent Use of Opioids and Benzodiazepines <ul style="list-style-type: none"> ▪ Safe and Effective Management of Patient Receiving Opioids and Benzodiazepines Concurrently provider letter - Upcoming RetroDUR Interventions: <ul style="list-style-type: none"> o Hepatitis C – Project Hep Cure <ul style="list-style-type: none"> ▪ Hepatitis C provider letter <ul style="list-style-type: none"> • Recommendations from the Board included sending the letter to the Medical Director of the clinic and replacing the stereotyping information with educational resources and opportunities. ▪ Josh presented the Project HepCure public facing dashboard - Potential RetroDUR Interventions: <ul style="list-style-type: none"> o Overutilization of Short-Acting Beta Agonist o Concurrent Use of Opioids and Stimulants
MO HealthNet Pharmacy Overview	<p>Joshua Moore, Angela Wilson and Olivia Rush provided a presentation on MHD Pharmacy Overview.</p> <ul style="list-style-type: none"> - No other discussion. - No other public comment provided.

Motion to Close	Rick Kegler motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.
------------------------	--

NEXT MEETING: Thursday, October 19, 2022
MO HealthNet, 615 Howerton Court, Conference Room 202
Jefferson City, MO 65109 and WebEx

DRAFT

Roll Call for July 20, 2022				
	<u>Action Item</u>			
<u>Board Member</u>	April Meeting Minutes	All Recommendations: Block Vote for CE, FE and PDL Edits	Closing	Adjournment
Susan Abdel-Rahman	Y	Y	Y	Y
Charlene Heyde	Y	Y	Y	A
Sandra Bollinger	A	A	A	A
Julie Ferguson	Y	Y	Y	Y
Lisa Pierce	Y	Y	Y	A
Jennifer Passanise	A	A	A	A
Stacy Mangum	A	A	A	A
Ginger Nicol	Y	Y	Y	A
Rick Kegler	MY	MY	MY	SY
Kim Eisenstein	SY	SY	SY	MY

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain